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In many diseases, expression and ligand-dependent activity of the p75NTR receptor can promote pericyte and vascular dysfunction,
inflammation, glial activation, and neurodegeneration. Diabetic retinopathy (DR) is characterized by all of these pathological events.
However, the mechanisms by which p75NTR may be implicated at each stage of DR pathology remain poorly understood. Using a
streptozotocin mouse model of diabetic retinopathy, we report that p75NTR is upregulated very early in glia and in pericytes to mediate
ligand-dependent induction of inflammatory cytokines, disruption of the neuro-glia-vascular unit, promotion of blood–retina barrier
breakdown, edema, and neuronal death. In a mouse model of oxygen-induced retinopathy, mimicking proliferative DR, p75NTR-
dependent inflammation leads to ischemia and pathological angiogenesis through Semaphorin 3A. The acute use of antagonists of
p75NTR or antagonists of the ligand proNGF suppresses each distinct phase of pathology, ameliorate disease, and prevent disease
progression. Thus, our study documents novel disease mechanisms and validates druggable targets for diabetic retinopathy.
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Introduction
Diabetic retinopathy (DR) is a major cause of reduced vision in
the working age population (Yau et al., 2012) and leads to irre-
versible vision loss in75% of patients (Heng et al., 2013). DR is
a retinal disorder that is characterized by several distinct phases,
such as loss of the blood–retina barrier (BRB) function and cap-
illary loss leading to diabetic macular edema (DME). DME is
characterized by extravasation of fluids from retinal circulation
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Significance Statement
Diabetic retinopathy (DR) affects an estimated 250million people and has no effective treatment. Stages of progression comprise peri-
cyte/vascular dysfunction, inflammation, glial activation, and neurodegeneration. The pathophysiology of each stage remains unclear.
We postulated that the activity of p75NTRmay be implicated.We show that p75NTR in glia and in pericytesmediate ligand-dependent
inductionof inflammatory cytokines, disruptionof theneuro-glia-vascularunit, promotionofblood–retinabarrierbreakdown, edema,
and neuronal death. p75NTR-promoted inflammation leads to ischemia and angiogenesis through Semaphorin 3A. Antagonists of
p75NTRor antagonists of proNGF suppress each distinct phase of pathology, ameliorate disease, and prevent disease progression. Our
study documents novelmechanisms in a pervasive disease and validates druggable targets for treatment.
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into the retina, which can lead to significant decreases in visual
acuity (Antonetti et al., 2012; Yau et al., 2012). Later stages are
associated with retinal ischemia causing hypoxia and a subse-
quent phase of VEGF-mediated neovessel growth or proliferative
DR (PDR). Preventing destructive angiogenesis remains the only
current treatmentmodality for PDR (Antonetti et al., 2012; Heng
et al., 2013).
Accumulating evidence points to defects of the neurovascular
unit (neurons, glia, and vessels) (Binet et al., 2013; Cerani et al.,
2013; Joyal et al., 2013; Dejda et al., 2014) throughout the pro-
gression of DR and during pathological preretinal neovascular-
ization (NV), suggesting that the pathophysiology of DR is not
purely vascular in nature (Abcouwer and Gardner, 2014). For
instance, retinal oxidative stress resulting from hyperglycemia
and hyperlipidemia (Kowluru and Chan, 2007) contributes to
glial dysfunction and activation (gliosis) (Bringmann et al., 2006;
Coorey et al., 2012), inflammation induced by resident glia (Mu¨l-
ler cells), and death of the specific neuronal cell populations (ret-
inal ganglion cells [RGCs]) (Ali et al., 2008), which intriguingly
precede any observable clinical vascular irregularities or neuronal
cell dysfunction in diabetes (Fletcher et al., 2007; Abcouwer and
Gardner, 2014). However, although these studies highlight the
premature changes that occur in the retina of diabetic patients, it
is not clear whether glial cell abnormalities precede neuronal
cell dysfunction or vice versa. Moreover, the pathophysiological
events that bring about these changes remain ill defined, and
currently no therapeutic strategies have been developed to
counter them. Thus, it is important to understand these early
changes in the neurovascular unit as theymay be complementary
to or even precede vascular abnormalities in diabetic patients.
The neurotrophin receptor p75 (p75NTR), which is highly ex-
pressed in astrocytes andMu¨ller cells inmanymodels of neuronal
damage, would be capable of mediatingmany of the pathological
events described above. In retinopathies, such as glaucoma or
optic nerve damage, p75NTR is upregulated and its ligand
proNGF can promote production of inflammatory cytokines
TNF (Lebrun-Julien et al., 2009a; b, 2010; Bai et al., 2010a) and
2-macroglobulin (2M) from glial cells (Shi et al., 2008; Bai et
al., 2011), which leads to RGC neurodegeneration. Moreover,
p75NTR is known to contribute to cardiac vasculopathies (Siao et
al., 2012), BRB breakdown, and fluid extravasation (Al-Gayyar et
al., 2011; Mysona et al., 2013). These observations potentially
place p75NTR at a crossroads of all pathological components of
human DR: vascular defects, inflammation, and neurodegenera-
tion. However, the mechanism by which p75NTR mediates these
potentially sequential pathophysiological events during diabetes
remains poorly understood.
Here, we use a streptozotocin (STZ)-inducedmousemodel of
diabetes causing BRBbreakdownwith edema, inflammation, and
RGC death; and an oxygen-induced retinopathy (OIR) mouse
model to study pathological NV. We demonstrate a rapid and
persistent increase of both proNGF and p75NTR at early stages of
disease. The p75NTR increase occurs in Mu¨ller cell glia and in
pericytes around the vasculature. p75NTR activity in Mu¨ller glia
augments inflammatory cytokines TNF and 2M, which per-
form two paracrine functions. First, TNF stimulates RGCs to
secrete the vascular cue Semaphorin 3A, a soluble factor known
to cause BRB breakdown and plasma extravasation (Cerani et al.,
2013; Joyal et al., 2013). Second, TNF and 2M cooperate to
promote RGC death in a proNGF and p75NTR-dependent man-
ner. Diabetes-induced BRB breakdown and edema, production
of inflammatory cytokines, and RGC death are significantly di-
minished for prolonged periods upon acute administration of
inhibitors of proNGF or p75NTR; and both the vaso-obliteration
(VO) and NV phases are significantly diminished in the mouse
model of OIR. Thus, p75NTR and proNGF are key pathological
mediators within the neuro-glia-vascular unit andmay be poten-
tial therapeutic targets for various stages ofDRpathology, includ-
ing the DME, PDR, and neurodegenerative components; and
offer an alternative to VEGF-based strategies to limit vascular
abnormalities.
Materials andMethods
Animals. All experiments were conducted in accordance with Associa-
tion for Research in Vision and Ophthalmology statement regarding use
of animals in ophthalmic and vision research and were approved by all
Institutional Animal Welfare Committees.
Female andmale adult C57BL/6J (WT)micewere purchased fromThe
Jackson Laboratory and coupled for litter production in the Animal Care
facility at Maisonneuve-Rosemont Hospital Research Center (Montreal,
Quebec, Canada). Adoptive CD-1 lactating females were purchased from
Charles River Laboratories to tend to hyperoxia-exposed pups.
Induction of diabetes. Male 10-week-old mice (24 g) received an
intraperitoneal injection of STZ (60mg/kg) (Sigma-Aldrich) dissolved in
sodium citrate buffer (0.01 M, pH 4.5) on 5 consecutive days. After 1 and
6 weeks of injection with STZ, blood glucose was measured using a glu-
cometer (Abbott Laboratory), and fasting blood glucose levels 17
mmol/L (300 mg/dl) (Mysona et al., 2013) were considered to be dia-
betic. Age-matched, nondiabetic C57BL/6 mice injected with sodium
citrate buffer were used as controls. Fasting blood glucose levels were
measured routinely. As example, a control group was 7.89  0.69 mM,
and the STZ group was 28.81 4.204 mM (p 0.001, n 12).
OIR. Newborn mice pups were exposed for 5 d to 75% oxygen from
postnatal day 7 (P7) to P12. VO and NV were assessed in hyperoxia-
exposed mice pups at P12 and P17, respectively, as described previously
(Smith et al., 1994; Stahl et al., 2010). Briefly, mice pups were fully anes-
thetized in 3% isoflurane in oxygen and killed using a guillotine. Eyes
were enucleated and fixed in 4% PFA solution for 60 min at room tem-
perature. Retinas were dissected and stained overnight at 4°C with
fluorescein-labeled GSL 1, isolectin B4 (FL 1201, Vector Labs; 1:100).
Lectin-stained retinas were whole-mounted onto Superfrost/Plusmicro-
scope slides (Fisher Scientific) with the photoreceptor side down and
imbedded in Fluoro-gel (Electron Microscopy Sciences) and photomi-
crographed at 10 using a Zeiss AxioObserver.Z1. Images were pho-
tomerged into a single file using the MosiaX option in the AxioVision
4.6.5 software. Quantification of VO and NV was assessed using the
SWIFT_NV methods as previously described (Stahl et al., 2009).
Optical coherence tomography (OCT) imaging. A noninvasive proto-
type spectrometer-based FD-OCT system was used to acquire the retinal
images. FD-OCT is a noninvasive method that allows time-kinetic stud-
ies in the same animal, with axial resolution in tissue nominally better
than 3 m and repeatability of the measurements from B-scans better
than 1m. Data acquisition was performed using custom software writ-
ten in C2 for rapid frame grabbing, processing, and display of 2D im-
ages (Li et al., 2011; Jian et al., 2013). B-scan images were segmented
manually to quantify the thicknesses of the different retinal layers.
Mice were anesthetized using isoflurane/O2 and placed on a platform,
and the head was oriented to an angle at which the eye was properly
aligned to the optical beam. The pupils were dilated with a topical solu-
tion (atropine sulfate 1%; Alcon). Refraction of light at the cornea was
cancelled by placing over the eye a generic artificial tear gel. Alignment of
the optical system to the mouse retina required a few minutes and was
followed by rapid acquisition of data (5 s/vol). During retinal scanning,
three volumes were acquired in different sectors of the retina containing
theONhead as landmark. After processing, three B-scanswere randomly
selected from each volume. The retinal thickness measurements were
performed with MATLAB software (The MathWorks). In each B-scan,
the thickness of the nerve fiber layer/ganglion cell layer (GCL)/inner
plexiform layer (IPL), hereafter referred to as NGI (Saragovi et al., 1998;
Bai et al., 2010a), wasmeasured at three adjacent points. For each B-scan,
the thickness of the inner nuclear layer (INL) and outer nuclear layer
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Figure 1. Expression and localization of p75 NTR and neurotoxic factors increase during the progression of DR. The experimental paradigm and the endpoints of themouse DRmodel are shown.
Drug treatmentswere injected intravitreally atweek 2.5 of diabetes in this paradigm.A, p75 NTR, proNGF, TNF, and2Mexpression inwholemice retina analyzed byWestern blot from1–6weeks
after induction of diabetes. There were increases of p75 NTR during week 1, of proNGF during week 3, of TNF during week 4, and of2M during week 5. B, Quantification. *p 0.05, relative to
control.n3 independent experiments, eachwithn4mice/group. Statistical analysiswasdonebyapplyingone-wayANOVAwith significance establishedat0.05, followedbyBonferroni’s
correction for multiple comparisons. The 32–37 kDa bands of proNGF were quantified, and data are identical when the major band alone is quantified. C, Confocal microscopy (Figure legend continues.)
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(ONL), unaffected in the disease model, was also quantified as internal
controls. Data are shown as average  SEM thickness in micrometers
(absolute values) in control versus diabetic-injected intravitreally once
with either vehicle (PBS, 1% DMSO), THX-B, a pharmacological small-
molecule antagonist of p75NTR (Bai et al., 2010a;Mysona et al., 2013), or
anti-proNGF NGF30 mAb (Saragovi et al., 1998; Bai et al., 2010a).
THX-B is an antagonist of ligand-dependent and ligand-independent
activity of p75NTR, and a competitive blocker of proNGF binding to
p75NTR. The anti-proNGF mAb blocks proNGF binding to p75NTR, as
well as the binding ofmature NGF to p75NTR, but does not affect mature
NGF binding or activity at TrkA.
Intravitreal injections.Mice were anesthetized in 3% isoflurane during
intravitreal injections of clear solutions of THX-B p75NTR antagonist,
neutralizing anti-proNGF mAb, or vehicle. In the diabetes model, adult
diabetic mice were injected at 2.5 weeks of diabetes. In the OIR model,
mouse pups were injected at P7, P9, P12, or P14. All solutions were
injected using a Hamilton syringe with 50 gauge glass capillary. The
intraocular injections were in 2 l volumes containing a total of 2 g
THX-B or 2 g anti-proNGF NGF30 mAb as described for glaucoma
(Shi et al., 2008; Bai et al., 2010a).
TUNEL assays and image analyses of flat-mounted retinas. The eyes
were collected and retinas were dissected for flat-mounting and TUNEL
staining; n 4mice per group. Control nondiabetic animals and diabetic
animals were studied. One eye of each mouse was injected intravitreally
once with either THX-B, or anti-proNGFmAb, or vehicle. Contralateral
untreated eyes were used as control. Retinas were processed and stained
with the DeathEnd Fluorometric TUNEL System as per the manufactur-
er’s instructions (Promega). Briefly, whole retinaswere dissected, fixed in
4% PFA overnight, and permealized with Proteinase K. Afterward, the
samples were postfixed and the TdT reaction was carried on at 37°C in
humidified chambers. TUNEL-labeled retinas were mounted with
Vectashield-DAPI to counterstain nuclei. For each flat-mounted whole
retina, three digital images per quadrant (superior, temporal, inferior,
and nasal) were taken using confocal fluorescence microscopy at 20
magnification, for a total of 12 images per retina taken in a blinded
fashion (n 4 retinas per group). Images were taken at 0.5–0.7, 1.0–1.2,
and 2.0–2.2 mm distances from the optic disc (areas 1, 2, and 3, respec-
tively) and analyzed per area to account for known variations in RGC
density in each area, as described previously (Bai et al., 2010a). Total
TUNEL-positive cells and total nuclei of RGCs were counted in each
picture. Each 20magnification field exposes 0.2285 mm2; and in each
independent experiment, images spanning 10.97–21.93 mm2 per group
were analyzed.
RGC and fiber counts. The cornea, lens, and vitreous body were re-
moved and the retina was dissected out for flat-mounting (Esquiva et al.,
2013). After blocking (10% normal donkey serum in phosphate buffer
plus 0.5%TritonX-100 for 1 h), the retinaswere incubated for 72 h at 4°C
with goat anti-Brn3a antibody (1:500; SantaCruzBiotechnology) diluted
in 0.1 M phosphate buffer containing 0.5% (v/v) Triton X-100 (Sigma) to
detect the RGC population (García-Ayuso et al., 2010, 2015). After wash
with phosphate buffer, the retinas were incubated overnight with the
secondary antibody AlexaFluor-488 donkey anti-goat IgG (1:500; Invit-
rogen). Then, the retinas were washed and flat mounted in mounting
medium (Citifluor) on glass slides with the GCL side up, and protected
with a coverslip for optical microscopy. Using MetaMorph software
(Leica MMAF 1.6) associated to a DMLA Microscope (Leica Microsys-
tems) entire flat-mount retinas were photographed at 20 magnifica-
tion. High-magnification pictures were taken using a laser-scanning
confocal microscope (TCS SP2, Leica Microsystems). Brn3a-positive
cells in the GCL were quantified at 0.5–0.7, 1.0–1.2, and 2.0–2.2 mm
distances from the optic disc (areas 1, 2, and 3, respectively) using image-
editing software (Photoshop 10.0; Adobe). Mean density (number of
cells permm2) values were calculated for all the different areas. A total of
4 retinas per experimental group were analyzed.
FISH. The digoxigenin (DIG) RNA labeling kit (Roche) was used to
generate the DIG-labeled probes. Efficient labeling was verified in aga-
rose gels (1%). After enucleation, the eyes were immersed overnight in
fixative at 4°C (4% PFA in PBS, pH 7.4), followed by cryoprotection in
30% sucrose overnight at 4°C. Eyes were embedded in OCT tissue TEK
(VWR) and frozenwith dry ice. Cryostat-cut sections (20mthick)were
mounted onto gelatin-coated glass slides, refixed in 4% PFA, permeabil-
ized with proteinase K, and acetylated. Hybridization was carried by
incubating the slides with either 200 ng/ml of DIG-labeled TNF or2M
antisense RNAs probes overnight at 72°C in a hybridization oven (Rob-
bins Scientific). As controls, hybridization with either 200 ng/ml of
DIG-labeled TNF or 2M sense RNAs probes was performed on paral-
lel slides using the same experimental conditions. Hybridization was
followed by nonstringent and stringent washes, and incubation with
anti-DIG-HRP (1:1000) overnight at 4°C. The amplification reactionwas
performed using the TMR-conjugated TSA kit (PerkinElmer) following
manufacturer protocols. Finally, sections were washed and coverslipped
using Vectashield mounting media with DAPI (Burlingame). The slides
were analyzed by confocal microscopy.
Vascular permeability assay. Evans Blue permeation was analyzed by
measuring albumin-Evans blue complex leakage from retinal vessels as
previously described (Ma et al., 1996). Briefly, animals were injected
intravenously with a solution of Evans blue (2% w/vdissolved in PBS).
After 48 h, animals were killed, the whole eyes were enucleated, immedi-
ately embedded in OCT compound and cross sections were prepared.
Microphotographs by immunofluorescence microscopy were obtained
using identical exposure time, brightness, and contrast settings. For each
experimental condition, at least 6 images were acquired from 3 sections
cut from different areas of the retina (n 3 retinas per group). The area
of the Evans Blue permeation was measured using ImageJ software. For
the in situ studies, an arbitrary rectangle was drawn that include all layer
of the retina (GCL, IPL, INL, and ONL) to measure the Evans Blue
staining using ImageJ. Data are shown as the average area (in pixels) 
SEM in control versus diabetic injected once with vehicle, anti-proNGF
mAb, or small-molecule p75NTR antagonist THX-B.
Immunohistochemistry.Whole eyes were enucleated frommice pups or
adult and immediately fixed in 4% PFA at room temperature for 2 h. Eyes
were saturatedovernight at 4°C in a 30%sucrose solutionbefore embedding
inOCTcompound(24608–930,TissueTek).Retinal cross sectionsof10m
were sectioned using a Cryostat (Leica). Sections were subsequently washed
withPBS,permeabilized for60minat roomtemperaturewith3%BSA,0.2%
Triton X-100, and 0.05% Tween20 in PBS, and stained with antibodies to
mouse p75NTR (1:1000; a kind gift from Dr. R. Rush) or rabbit p75NTR
(1:1000; a kind gift fromDr. P. Barker), rabbit glutamine synthetase (16802,
Abcam; 1:200), mouse cellular retinaldehyde-binding protein (CRALBP,
15051, Abcam; 1:1000), rabbit GFAP (AB5804, Millipore, 1:1000), rat anti-
proNGF/NGFmAbNGF30 (1:2000) (Saragovi et al., 1998; Bai et al., 2010a)
prepared in house, rabbit TNF (AB2148P, Millipore, 1:1000), rabbit 2M
(1:1000, Santa Cruz Biotechnology) or mouse III-tubulin (T8578, Sigma-
Aldrich; 1:1000). Fluoresceinated secondary antibodies (goat anti-mouse
IgGAlexaFluor-488, -594, and/or -647 and goat anti-rabbit IgGAlexaFluor-
488, -594, and/or -647; Invitrogen)wereused for localization studies accord-
ing to manufacturers’ recommendations. Images were obtained using an
IX81 confocal microscope (Olympus) equipped with Fluoview 3.1 software
(Olympus). As controls during immunostaining, adjacent sections were
processed equally but without primary or with irrelevant primary, followed
by the proper secondary. In all cases, background levels are undetectable.
Western blot. Eyes were enucleated and retinas immediately dissected
and placed into protein lysis buffer and briefly homogenized. Samples
(combined retinal lysate from two different animals) were centrifuged
and 30 g resolved on an SDS-PAGE gel (8%–12%) and electro-blotted
4
(Figure legend continued.) images show induction and distribution of p75 NTR in mice retina
after 6 weeks of diabetes comparedwith age-matched control animals. p75 NTR (red) was pref-
erentially expressed in Mu¨ller cells (green, white arrows in insets pointing at the end-feet of
Mu¨ller cells), as revealed by coexpression with CRALBP, and around the vessels where p75 NTR
(red,white arrows in insets pointing at the vessels in theouter plexiform layer)was coexpressed
with GFAP, a specific marker of active Mu¨ller and astrocyte cells (green). Nuclei are counter-
stained with DAPI. White rectangles represent magnified areas (40) shown in the insets.
Scale bar, 30m. PhR, Photoreceptor layer; OLM, outer limiting membrane; RPE, retinal pig-
ment epithelium.D, Flat-mounted retinas from the same animals showpartial colocalization of
p75 NTR (green) with NG2 (red) pericyte marker around vessels. Scale bar, 100m.
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onto either PVDF or nitrocellulose membranes (Bio-Rad). Membranes
were washed, blocked for 60 min in 5% milk in TBS-Tween, and incu-
bated overnight at 4°C with mouse antibody to -actin (sc-47778, Santa
Cruz Biotechnology; 1:1000), rabbit antibody to p75NTR (1:1000; a kind
gift from Dr. P. Barker), rabbit TNF (AB2148P, Millipore, 1:2000),
rabbit 2M (Santa Cruz Biotechnology; 1:2000), and rat proNGF/NGF
(1:200). After washing, membranes were incubated with 1:5000 HRP-
conjugated anti-mouse or 1:2000 HRP anti-goat or -rabbit secondary
antibodies (Millipore) for 2 h at room temperature. Membranes were
imaged with LAS-3000 imager (FujiFilm), and bands were assessed using
densitometry plugins inMulti Gauge 4.0 software (FujiFilm). The size of
bands reported are Mr calculated using standard markers.
Cell culture. Rat brain microvascular endothelial cells (RBMVECs)
were obtained from Cederlane Laboratories and used between passages
2–7. rMC-1 cells were cultured in low glucose DMEM (Invitrogen) sup-
plemented with 10% FBS and 1% penicillin/streptomycin at 37°C
and 5% CO2, whereas RBMVECs were cultured as described by manu-
facturer’s instructions. Cells were starved 4 h before treatment with 0.1,
1.0, or 10.0 ng/ml of recombinant proNGF (CYT-426, ProSpec). Neu-
tralizing antibody to proNGF was used at 1 g/ml, whereas THX-B was
used at 4 g/ml. Proteins were extracted using protein lysis buffer and
lysates processed forWestern blot analysis. Total RNAwas isolated using
TriZol (Invitrogen) and analyzed via RT-PCR and qPCR analysis.
Reverse-transcription PCR and quantitative real-time PCR.Cell culture
and retinas samples were processed using TriZol (Invitrogen) as de-
scribed by themanufacturer’s instructions. Subsequently, genomic DNA
was removed using DNase I (Invitrogen) as described by the manufac-
turer’s instructions. Total RNA (1 g) was reverse-transcribed into
cDNA using iScript RT Supermix (Bio-Rad) following the indications of
the manufacturer. cDNA was analyzed by quantitative real-time PCR on
the ABI 7500 Real-Time PCR system (Applied Biosystems) and using iQ
SYBR Green Supermix (Bio-Rad) with primers targeting Semaphorin
3A, TNF, and -actin (designed using primer3 [NCBI]). The primers
were used to generate specific fragments: rat TNF forward, 5	 CTAT
GTGCTCCTCACCCACA 3	, reverse 5	 TGGAAG ACTCCTCCCAGG
TA 3	; mouse TNF forward, 5	GAGTCCCAGGTCTACTTT 3	, reverse
5	CAGGTCACTGTCCCAGCATCT 3	; andmouse Semaphorin 3A for-
ward, 5	 GGGACTTCG CTATCTTCAGAAC 3	, reverse, 5	 GGCGT-
GCTTTTAGGAATGTTG 3	. All primers were used at 100 nM. The
reaction was performed in triplicate with an Mx3000P QPCR System
(Stratagene). Amplification reaction data were analyzed using the com-
plementaryMx3000P analysis software. Target gene expression was nor-
malized to the average expression of the housekeeping gene GAPDH
forward 5	 CACCACCTTGATGTCATC-3	, reverse 5	AGCCCAGAAC




Preparation of rMC-1 conditioned media (CM). rMC-1 were seeded
(106 cells) and starved 4 h before treatment with 1.0 ng/ml of recombi-
nant proNGF (CYT-426, ProSpec). Supernatants were collected 24 h
later, cleared by centrifugation, filtered through 0.22 m filters (Milli-
pore), and distributed for cell survival assays (see below).
Cell survival assay. Approximately 104 RBMVEC cells/well were
seeded in 24 well plates and starved 4 h before exposure to rMC-1 CM.
Neutralizing antibody to proNGF was used at 1 g/ml, whereas THX-B
was used at 4 g/ml. After 24 h, 50 l of a 5 g/ml solution of thiazolyl
blue tetrazolium bromide (M2128; Sigma) was added to each well and
cells incubated for 2–3 h. Subsequently, the supernatant was aspirated
and cells were lysed and resuspended in acidified isopropanol and shaken
for 5 min. Duplicate absorbance readings were taken at 565 nm using
Infinite M1000 Pro plate reader (TECAN).
Statistical analysis. Results are presented as mean SEM for all stud-
ies. One-way or two-way ANOVA with significance   0.05 or higher
were used for processing data. Bonferroni post hoc analysis was used for
calculating significance between groups. Two-tailed Student’s t tests were
used to test for significance between two means.
Results
Upregulated retinal p75NTR and proNGF in a mouse model of
Type 1 diabetes is followed by induction of proinflammatory
cytokines
To study the effects of p75NTR and its ligand proNGF in DR, we
determined their expression pattern in a STZmousemodel of Type
1 diabetesmellitus. Time-kinetic studies were performed by quanti-
tative Western blots on retinas collected from diabetic animals be-
tween weeks 1–6 following diabetes onset. At week 1 of diabetes,
retina p75NTR protein levels rose 2-fold compared with control
retinas (p  0.05, n  4). Retina proNGF protein expression in-
creased2-fold atweek 3 of diabetes comparedwith control retinas
(p 0.05, n 4). Significantly higher retinal levels of p75NTR and
proNGF persisted for at least 6 weeks of diabetes compared to con-
trol retinas (Fig. 1A, quantified in Figure 1B).
In some retinal neurodegenerative diseases, such as optic
nerve axotomy or glaucoma, proNGF-mediated toxicity affects
non–p75NTR-expressing cells, suggesting a non–cell-autologous
process. Indeed, in human and rodent disease, p75NTR and
proNGF upregulate two proteins 2M (Bai et al., 2010a, b, 2011)
and TNF (Lebrun-Julien et al., 2009a, 2010; Bai et al., 2010a, b,
2011) secreted from Mu¨ller glia, which contribute to neurode-
generation (Bai et al., 2011; Barcelona and Saragovi, 2015).
Hence, we studied these proteins as a putative mechanism that
can perturb glial function, induce neuronal apoptosis, and cause
vascular perturbations in the STZ model of diabetes. In diabetic
retinas,2M protein levels increased1.5-fold at week 5 compared
with controls (2M, 1.641  0.149; p  0.05, n  4) and TNF
protein levels surged 2-fold increase at week 4 compared with
controls (TNF, 2.12 0.193; p 0.05, n 4) (Fig. 1A, quantified
in Figure 1B). Essentially, sequential upregulation of p75NTR and
proNGF is associated time-dependently with an increase in TNF
and 2M that can be proinflammatory and neurotoxic.
Retinal p75NTR is upregulated in activatedMu¨ller cells,
astrocytes, and vascular pericytes in a mouse model of
Type 1 diabetes
Immunohistochemical studies in retinal sections demonstrated
increased expression of p75NTR in Mu¨ller cells identified by
CRALBP; and in the periphery of vessels, the nerve fiber and
GCLs, andMu¨ller cell end-feet and astrocytes labeled with GFAP
(Fig. 1C). p75NTR levels were significantly elevated in diabetic
retinas compared with control animals, which corroborates the
Western blot analysis. The elevated p75NTR label in the periphery
of vessels of diabetic retinas seen in cross sections was studied in
whole flat-mounted retinas. The elevated p75NTR label corre-
sponds to vascular pericytes also labeled with the NG2 marker
(Fig. 1D). In these whole flat-mounted retinas, the p75NTR label
(green) that appears beneath the pericytes corresponds toMu¨ller
cell fibers and astrocytes. Similar data were obtained using other
pericyte markers (PDGF-receptor; data not shown).
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Figure 2. The expression of the cytotoxic molecules TNF and 2M is increased in Mu¨ller
cells duringDR.A, FISH shows induction anddistribution of DIG-labeled TNFor2Mantisense
RNAs probes (red) inmice retina after 6weeks of diabetes comparedwith age-matched control
animals. Nuclei are counterstained with DAPI. Scale bar, 30 m. Histograms represent the
quantification of the expression of TNF and2MmRNAs in the GCL, IPL, INL, outer plexiform
layer (OPL), and photoreceptor layer (PhR). Statistical analysis was done by applying one-way
ANOVA with significance at 0.05. *p 0.05, relative to control. **p 0.01, relative to
control. ***p 0.001 relative to control. n 3 independent experiments, each with n 4
mice/group. B, FISH followed by immunofluorescence showing colocalization of TNFmRNAs
(red)with p75 NTR protein (green) in the end-feet ofMu¨ller cells (white arrow, insets) and in the
IPL. Scale bar, 30m.White rectangles represent higher-magnification images (40) repre-
sented in the insets. Sense TNFmRNA hybridization was used on diabetic retina samples as a
negative control.
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Figure 3. Pharmacological inhibition of p75 NTR or proNGF preserves retinal structures where RGCs are located and inhibits RGC death in DR. A, Representative images of Brn3-labeled RGCs from
3 different retinal areas at concentric distances from the optic nerve: 0.5– 0.7 mm (area 1), 1.0–1.2 mm (area 2), and 2.0–2.2 mm (area 3). RGCs were quantified in (Figure legend continues.)
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2M and TNFmRNA in diabetes is upregulated primarily in
Mu¨ller glial cells
Because 2M and TNF are soluble factors, to determine their cel-
lular expressionpatterns,weperformed in situmRNAhybridization
on retinal sections of mice 6 weeks after STZ. Our results demon-
strate significant increases in TNFmRNA in the RGC layer (p
0.01), IPL (p 0.05), INL (p 0.01), andphotoreceptor layer (p
0.01) comparedwith control retinas (Fig. 2A). Interestingly,most of
the diabetes-induced upregulation of TNFmRNAwas seen in the
RGC layer and INL, themain retinal layers affected in DR. Further-
more, there was an increase in 2M mRNA in the RGC layer and
INL.Upregulationof2MmRNAwas alsodetected in theboundary
between the INL and photoreceptor layers, likely associated with
cells of the retinal vasculature in that location (Fig. 2A).Graphs show
significant changes quantified for TNF and 2MmRNAs in each
retinal layer.
Some of the TNFmRNA signal in the RGC layer colocalizes
with p75NTR protein in what are likely Mu¨ller cell end-feet. Con-
trol hybridization with TNF sensemRNAprobes showed unde-
tectable levels, confirming the specificity of the technique (Fig.
2B). Similar controls were obtained using2M sense probes (data
not shown).
Together, these data suggest that, in diabetic retinas, p75NTR,
expressed mainly onMu¨ller glia and astrocytes, contribute to the
production of 2M and TNF, which can be proinflammatory
and. neurotoxic and may contribute to the pathogenesis of dia-
betes through a paracrine mechanism.
Pharmacological inhibition of p75NTR or proNGF in diabetes
reduces RGC death and preserves retinal structures
Next, we evaluated whether elevated expression of p75NTR in
Mu¨ller glia, astrocytes, and pericytes impact neurodegeneration
associated with DR progression. To do this, we quantified RGC-
specific Brn3 staining, TUNEL staining, andOCTmeasurements
of retinal structure in diabetic retinas with or without therapeutic
treatment with a p75NTR small-molecule antagonist (THX-B) or
an anti-proNGF blocking mAb (Fig. 3) previously described as
having potent p75NTR inhibitory properties (Bai et al., 2010a).
Analyses and quantification were done at specified distances
from the optic disc (areas 1, 2, and 3, respectively) to account for
normal thinning of RGC density toward the periphery. After 6
weeks of diabetes, there was an15%-25% reduction in Brn3
RGCs in flat-mounted whole retinas, compared with control na-
ive retinas (area 1: 3450 413 vs 2787 219 cells/mm2, p 0.05;
area 2: 3215 284 vs 2095 250 cells/mm2, p 0.01) (Fig. 3A).
To test whether RGC loss in diabetic retinas is p75NTR- or
proNGF-dependent, animals were injected THX-B or anti-
proNGF mAb into the vitreous 2.5 weeks following onset diabe-
tes (contralateral eyes were injected with vehicle control).
Treatment with anti-proNGF mAb or THX-B preserved the
Brn3 RGCs counted at week 6 of diabetes (area 1: 3202  123
and 3350 98 cells/mm2, respectively, vs 2786 279 cells/mm2
vehicle-treated contralateral eyes, p  0.05; area 2: 2944  129
and 3310  378 cells/mm2, respectively, vs 2416  194 cells/
mm2 vehicle-treated contralateral eyes, p 0.001 and p 0.05,
respectively) (Fig. 3B).
To consolidate these results, we performed TUNEL staining
on retinal flat mounts obtained from 6 week diabetic mice that
had been injected 2.5 weeks following onset diabetes with
THX-B, proNGF mAb, or vehicle. TUNEL-positive staining was
significantly diminished in eyes receiving intravitreal injections
of THX-B or anti-proNGF mAb compared with vehicle-treated
contralateral eyes (Fig. 3C; p  0.05). The analyses of flat-
mounted retinas quantify the RGC layer containing RGC nuclei,
displaced amacrine cells, and astrocytes. Because astrocytes do
not die in this disease model, the TUNEL cells can only be RGC
neurons or displaced amacrine cells.
These data indicate that the reduced numbers of Brn3RGCs in
diabetic retinas occurs in a p75NTR-dependentmanner, an outcome
prevented by inhibition of p75NTR activity using THX-B or anti-
proNGF mAb. Moreover, the fact that p75NTR is not expressed in
RGCs suggest a non–cell-autonomousmechanism.
Further RGC layer quantification was performed by OCT, a
noninvasive method for measuring structural changes in vivo,
and which correlates with RGC numbers during neurodegenera-
tion (Sarunic et al., 2010). OCT was performed longitudinally in
animals from 1 to 6 weeks following onset of diabetes, measuring
RGC cell bodies and fibers in the nerve fiber layer, the GCL, and
the IPL termedNGI (Fig. 3D). In diabetic eyes, the NGI thickness
decreased progressively and was significantly lower after 5 weeks
of diabetes compared with age-matched nondiabetic eyes
(37.85 1.3 m vs 50.45 0.9 m; p 0.05).
Treatment of diabetic eyes with anti-proNGFmAb or THX-B
protected against NGI thinning (42.51 1.7mand 43.75 1.1
m, respectively, p  0.05 vs vehicle-treated contralateral dia-
betic eyes). Structural preservation of NGI by anti-proNGFmAb
or THX-B were still significant after 6 weeks of diabetes (42.42
0.9m and 44.67 1.9m, respectively; vs vehicle-treated con-
tralateral diabetic eyes 37.11 1.5 m, p 0.05) (Fig. 3D).
As internal controls, we quantified retinal layers that do not
change in diabetes (INL, containing the Mu¨ller and bipolar
cell bodies) as well as the cone and rods of photoreceptors that
make up the ONL. Combined, these data indicate that, in the
retinas of diabetic mice, ligand-dependent p75NTR activity
promotes effectors that contribute to RGC death, with result-
ing retinal structural changes specifically in the NGI. Given
the significant and selective loss of the nerve fiber layer thick-
ness, which comprises RGC axons and fibers, most of the
TUNEL cells must be RGCs.
In sum, a single injection of an antagonist of p75NTR or proNGF,
at week 2.5 of diabetes and with concurrent pathology, prevents
structural degeneration and RGC apoptosis for prolonged periods
lasting to at least week 6 of continuing diabetes.
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(Figure legend continued.) flat-mounted retinas at 2, 4, and 6 weeks after induction of dia-
betes. Scale bar, 20m. *p 0.05 versus control naivemice. **p 0.01 versus control naive
mice. ***p 0.001 versus control naive mice. B, Representative images of Brn3-labeled RGCs
in flat-mounted retinas in 6 week diabetic mice treatment at week 2.5 of diabetes with
anti-proNGF mAb, or THX-B, or vehicle, compared with age-matched naive control animals.
Scale bar, 20m. Anti-proNGFmAb or THX-B treatment prevents loss of RGCs in all areas: area
1, **p  0.01 (repeated-measures ANOVA); area 2, ***p  0.001 (repeated-measures
ANOVA); area 3, *p 0.05 (repeated-measures ANOVA). C, Representative pictures of TUNEL
cells in 6 week diabetic mice treatment at week 2.5 of diabetes with anti-proNGF mAb, or
THX-B, or vehicle, compared with age-matched naive control animals. Anti-proNGF mAb or
THX-B was significantly protective in all three areas. ***p  0.001 (repeated-measures
ANOVA).D, Representative sections of B-scanOCT images in 6week diabeticmice treatment
at week 2.5 of diabetes with anti-proNGF mAb, or THX-B, or vehicle, compared with age-
matchednaive control animals. Histogramrepresents time-dependent changes in the thickness
of the NGI layer SD (n 3 eyes). Note the progressive loss of NGI thickness in the vehicle-
treated diabetic vehicle retina. The NGI layers are where the RGCs bodies and RGC fibers are
located, whereas the structure of the other layers (INL and ONL) do not change (see vertical red
bars). Anti-proNGF mAb or THX-B treatment significantly protected the NGI layer structure at
weeks 5 and 6. *p 0.05 (two-way ANOVA with significance established at  0.05, fol-
lowed by Bonferroni’s correction for multiple comparisons). ns, Not significant.
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p75NTR-proNGF signaling axis in diabetes augments TNF
and2M neurotoxin release, which contribute to RGC loss
To elucidate themechanism by which p75NTR-proNGF signaling
mediates neuronal apoptosis, we studied levels of TNF and
2M. The levels of TNF mRNA were quantified by qPCR at 6
weeks of diabetes versus control. TNF mRNA levels increased
2-fold in diabetic mice (2.24 0.221; p 0.001 n 3mice per
group). In diabetic eyes treated with anti-proNGF mAb or
THX-B, however, TNF mRNA levels were significantly lower
comparedwith vehicle-treated contralateral diabetic eyes (1.21
0.145, p 0.01, or 1.59 0.421, p 0.01, respectively, p 0.01,
n  3 mice per group; Fig. 4A). Indeed, in diabetic eyes treated
with anti-proNGFmAb or THX-B, TNFmRNA levels were not
statistically different from normal naive control retinas.
Given that TNF mRNA is expressed in Mu¨ller glia (Fig. 2),
we studied proNGF/p75NTR regulation of TNF in the ratMu¨ller
cell line rMC-1 that express p75NTR (Barcelona and Saragovi,
2015), by qPCR. Treatment of rMC-1 cells for 24 h with recom-
binant proNGF caused increases in TNF mRNA, in a dose-
dependent manner (Fig. 4B). This effect was abrogated with
cotreatment with either THX-B or anti-proNGF mAb (Fig. 4C;
p  0.001 and p  0.01, respectively). Control treatments with
THX-B alone or anti-proNGF mAb alone did not affect baseline
TNF expression.
The TNFmRNA increase caused by proNGF is consistent with
reported TNF protein increase caused by proNGF in the rMC-1
cell line (BarcelonaandSaragovi, 2015).Moreover, it is reported that
proNGF and 2M synergize to stimulate production of TNF pro-
tein in the rMC-1cell line (Barcelona andSaragovi, 2015).Hence,we
quantified TNF and 2M protein in normal and diabetic retinas.
TNF and2M protein levels were significantly increased in retinas
of 6weekdiabeticmice comparedwithnaive controlmice (Fig. 4D).
The increase in diabetic animals was significantly reduced by treat-
ment with anti-proNGF mAb or THX-B compared with vehicle-
treated contralateral diabetic eyes (n 3mice per group).However,
it is noteworthy that, following treatmentwithanti-proNGFmAbor
THX-B, the p75NTR expression remained elevated, whereas treat-
ment with anti-proNGF mAb reduced the levels of proNGF
(Fig. 4D).
Immunohistochemical analysis of retinal sections from ani-
mals treated with anti-proNGF mAb or THX-B demonstrated
attenuation in TNF protein accumulated in and around the
end-feet of CRALBP-positive Mu¨ller cells and in the RGC layer
(Fig. 4E). Reduction of 2M immunostaining was also observed in
the proximity of vessels in all layers (Fig. 4F). These results indicate
that pharmacological inhibition of p75NTR or its proNGF agonist
attenuates retinal proinflammatory cytokines secretedbyMu¨ller glia
and other cells, which has the positive effect of ameliorating neuro-
degeneration in diabetic mice.
Inhibition of p75NTR or proNGF efficiently reduces
pathological vascular permeability in diabetic mice by
affecting Sema3A production in neighboring RGCs
Knowing that increased p75NTR activity promotes glial activation
and production of inflammatory cytokines (Fig. 4) and RGC
death (Fig. 3), we next explored how these events might impact
BRB breakdown and edema, an important pathophysiological
phenomenon of diabetic pathology.
Semaphorin3A (Sema3A) has been previously shown to in-
duce BRB breakdown in diabetic mice (Cerani et al., 2013), and
its expression is increased inRGCs by proinflammatory cytokines
(Joyal et al., 2013). To test whether TNF triggers Sema3A, we
treated the RGC5 neuronal cell line with recombinant TNF,
which significantly augmented Sema3AmRNA2-fold after 4 h
(p 0.001) (Fig. 5A).
At 8 weeks of diabetes, there is a significant4-fold increase
in Sema3A mRNA (p 0.001 compared with naive control ret-
inas). This Sema3AmRNA is presumably promoted by increased
TNF levels in diabetes. Because increased TNF levels in diabe-
tes are promoted by p75NTR activity, we testedwhether treatment
with anti-proNGFmAb or THX-B, injected intravitreally at week
2.5 of diabetes, affected Sema3AmRNA levels. Treatment caused
a partial but significant reduction in Sema3A mRNA compared
with vehicle-treated contralateral diabetic eyes (p 0.01, n 3)
(Fig. 5B); from 4-fold to 2.5-fold. However, Sema3A levels
are not normalized and remain significantly higher than in nor-
mal naive control retinas.
Lower Sema3A production during diabetes leads to dimin-
ished BRBbreakdown and reduced Evans blue vascular leakage at
8 weeks of diabetes. Intravitreal injections of anti-proNGF mAb
or THX-B, at week 2.5 of diabetes, caused 85% and 65% decrease
in vascular leakage, respectively (p  0.001 compared with
vehicle-treated contralateral diabetic eyes, n  3 independent
experiments with a total of 12 mice) (Fig. 5C). It should be noted
that extravasation of fluid from the vasculature contains high
levels of2M, which is present in serum at a concentration of 2–4
mg/ml (Barcelona and Saragovi, 2015). Importantly, reducing
extravasation also helps to prevent 2M (and perhaps other fac-
tors) from reaching the retinal stroma after BRB breakdown.
In sum, proNGF and p75NTR-dependent Mu¨ller cell glia local
production of TNF and 2M stimulates Sema3A production by
RGCs, leading to BRB breakdown and edema, with further accu-
mulation of serum components, such as 2M, which potentiate
inflammation and cause RGC death. All these events can be ame-
liorated using antagonists of proNGF or p75NTR.
Pharmacological inhibition of p75NTR diminishes oxygen-
induced VO and inhibits microvascular endothelial cell death
VO and NV take place in human diabetes; however, the phase of
pathological NV does not occur in themouse STZmodel. Hence,
we used thewell-establishedmousemodel ofOIR to elucidate the
role of p75NTR-proNGF signaling axis during the VO and NV
phases of disease. Mouse pups were exposed to 75% oxygen for
5 d (from P7 to P12), and retinal levels of p75NTR, NGF, and
proNGF protein were quantified byWestern blot. During the VO
phase, proNGF was significantly increased (p 0.001) and ma-
ture NGF was significantly decreased (p  0.001) (Fig. 6A). In
contrast, there was no change in p75NTR expression (Fig. 6A),
which may be attributed to already elevated baseline levels of
p75NTR normally required for retinal pruning and development
during the first 14 d of postnatal life (Frade et al., 1999).
Next, to determine whether p75NTR activity was relevant in
VO, mice were injected intravitreally with THX-B at P7 OIR
(because VO occurs within the first 48 h). THX-B-treated pups
displayed significantly lessVO (p 0.01) comparedwith vehicle-
injected OIR pups at P12 OIR (Fig. 6B). These results are consis-
tent with our data on diabetic animals treated with THX-B or
anti-proNGF mAb, which also showed reduced vascular pathol-
ogy, decreased levels of TNF and Sema3A, reduced RGC death
and structural changes in the NGI layer, and reduced BRB
breakdown.
We next set out to determine whether p75NTR-dependent VO
in OIR is mediated by TNF and whether protection of VO by
THX-B occurs via inhibition of TNF and/or Sema3A.
Quantitative PCR at P9 showed significantly reduced produc-
tion of both retinal TNF mRNA (p  0.001) and Sema3A
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Figure4. Pharmacological inhibition of p75 NTR or proNGF prevent elevation of TNF and2M in DR. The levels of TNF transcriptwere quantified by quantitative real-time PCR.A, Retinas from
6 week diabetic mice treatment at week 2.5 of diabetes with anti-proNGF mAb, or THX-B, or vehicle, compared with age-matched naive control animals (n 3/group). **p 0.01 (two-way
ANOVAwith significance 0.05, followed by Bonferroni’s correction). ***p 0.00 (two-way ANOVAwith significance 0.05, followed by Bonferroni’s correction).B, rMC-1 glial cells were
treatedwith varying concentrations of recombinant proNGF for 24 h, and TNFmRNA levelswere quantified. *p 0.05 (one-wayANOVAwith significance 0.05). n 6. C, rMC-1 cells treated
with 1 ng/ml proNGF in the presence or absence of anti-proNGF mAb or p75 NTR inhibitor THX-B. Both treatments inhibited proNGF-induced TNF mRNA increases. (Figure legend continues.)
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mRNA (p  0.01) in THX-B-treated compared with vehicle-
treated OIR pups (Fig. 6C,D). Given that TNF can also affect
vessel integrity, we asked whether proNGF/p75NTR-mediated
increases in TNF affect endothelial cell survival. We treated
RBMVECs with CM from proNGF-stimulated rMC-1 cells and
measured cell survival. Media from proNGF-stimulated rMC-1
caused an 70% reduction in survival (p  0.001) compared
with CM from vehicle-treated rMC-1. CM from rMC-1 cells
treated with proNGF and either THX-B or anti-proNGF mAb
did not promote the death of RBMVECs. As control, direct treat-
ment of RBMVECs with proNGF had no effect on survival (Fig.
6E). Together, these results indicate that in OIR, as well as in
diabetes, proNGF induces TNF production in a p75NTR-
dependent manner, which may cause endothelial cell death and
contribute to the VO.
Pharmacological inhibition of p75NTR diminishes
pathological NV in OIR
We next characterized neurotrophic changes during the neovas-
cular phase of OIR. Although there were no detectable changes in
protein levels of proNGF or mature NGF in OIR compared with
normoxia (data not shown), the protein levels of p75NTR were
significantly increased in OIR at P14 (p  0.01) and P17 (p 
0.001) (Fig. 7A). Immunofluorescence of retinal sagittal sections
from P17 OIR mice demonstrated a preferential increase of
p75NTR in glutamine synthetase-positiveMu¨ller cell end-feet and
in GFAP cells in P17 OIR compared with normoxia (Fig. 7B).
There was also an increase in p75NTR in astrocytes surrounding
lectin-positive vascular endothelial cells (Fig. 7B). These results
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(Figure legend continued.) **p  0.01 (two-way ANOVA with significance   0.05).
***p 0.001 (two-way ANOVAwith significance 0.05). n 7 or 8. Anti-proNGFmAb or
THX-B in the absence of 1 ng/ml proNGF, as controls, had no effect. D, p75 NTR, proNGF, TNF,
and 2M expression in whole retina analyzed by Western blot of 6 week diabetic mice
treatment at week 2.5 of diabetes with anti-proNGF mAb or THX-B or vehicle, compared with
age-matched naive control animals. Both treatments significantly prevented the increased
TNF and 2M, without affecting p75
NTR levels. As expected, the anti-proNGF mAb reduced
the level of proNGF protein. Histograms show quantification relative to control or to the group
indicated by each bracket. *p 0.05 (two-way ANOVA with significance 0.05, followed
byBonferroni’s correction). **p0.01 (two-wayANOVAwith significance0.05, followed
by Bonferroni’s correction). ***p 0.001 (two-way ANOVA with significance 0.05, fol-
lowed by Bonferroni’s correction). n 3 independent experiments. E, F, Representative con-
focalmicroscopy images depicting the expression of TNF and2M in retina sections of 6week
diabetic mice treatment with anti-proNGFmAb or THX-B or vehicle at week 2.5 of diabetes,
compared with age-matched naive control animals. TNF (green) was localized around the
end-feet of CRALBP-positive (red) Mu¨ller cells around GCLs, whereas 2M (green) showed a
diffuse pattern of staining around vessels and surrounding the somata of cells in the GCL. The
expression of both TNF and2Mwas reduced ondiabeticmice treatedwith anti-proNGFmAb
or THX-B compared with vehicle-treated mice. Nuclei are counterstained with DAPI. Scale bar,
30m. NFL, Nerve fiber layer; RPE, retinal pigment epithelium; ns, not significant.
Figure5. Inhibitionofp75NTRorproNGFefficiently reducespathologicalvascularpermeability inDR.Quantificationof the levelsofSema3AtranscriptbyqPCRon(A)Retinalneuronal cell line(RGC5) treated
for 2, 4, and8hwith TNF. Sema3A increased over time, comparedwith basal levels. ***p0.001 (one-wayANOVAwith significance0.05).n6.B, Retinas of 8weekdiabeticmice treatment at
week 2.5 of diabetes with anti-proNGF mAb or THX-B or vehicle, compared with age-matched naive control animals. Anti-proNGF mAb or THX-B significantly decreased Sema 3A mRNA compared
withcontralateraldiabeticvehicle-treatedretinas.**p0.01(two-wayANOVAwithsignificance0.05followedbyBonferroni’scorrectionformultiplecomparisons).***p0.001(two-wayANOVAwith
significance 0.05 followed by Bonferroni’s correction for multiple comparisons). n 5. C, Confocal images of retinal sections from 6 week diabetic mice treatment at week 2.5 of diabetes with
anti-proNGFmAborTHX-Borvehicle, comparedwithage-matchednaivecontrolanimals.Redsignal represents leakageofEvansbluedyefromthevasculature intotheretina. Imagesarerepresentativeof three
independent experiments. Scale bar, 30m.Datawerequantifiedusing ImageJ as the averagepixel areaSD. **p0.01 (two-wayANOVAwith significance0.05 followedbyBonferroni’s correction
formultiple comparisons). ***p 0.001 (two-wayANOVAwith significance 0.05 followedbyBonferroni’s correction formultiple comparisons).n 3 independent experiments. ns, Not significant.
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indicate increased expression of glial p75NTR during the neovas-
cular phase of OIR and suggest a potential role in NV. Interest-
ingly, these phenotypic results are similar to what we detected in
diabetic mice.
Todetermine the contribution of p75NTR to the phase of path-
ological angiogenesis in OIR, pups were injected intravitreally
with THX-B at P12. Treatment with THX-B led to significantly
reduced avascular area and to significantly reduced pathological
NV at P17 compared with vehicle-injected mice (p 0.05) (Fig.
7C). Interestingly, administration of THX-B at P14 had no effect
on avascular area or on NV at P17, supporting the notion that
p75NTR activity is relevant during the early phases of NV.
THX-B inhibits VO during a period when VEGF levels are
suppressed due to high oxygen tension (P7-P12). This suggests
that p75 inhibitors act independent of VEGF. Normalization of
Sema3A levels by THX-B treatment was significant in the vaso-
obliterative phase. Because Sema3A deviates regenerating retinal
vessels in the vasoproliferative phase (Cerani et al., 2013; Joyal et
Figure 6. Inhibition of p75 NTR or proNGF reduces endothelial death during the VO phase of OIR. A, proNGF, mature NGF, and p75 NTR expression in wholemice retina analyzed byWestern blot in
theVOphase of theOIR (P7-P12at 75%O2). ProNGF increased significantly duringoxygenexposure relative tonormoxia,whereas expressionofmatureNGFdecreased significantly followingoxygen
exposure (mature NGF is a 26 kDa dimer in nonreduced SDS-PAGE). p75 NTR did not show significant changes. Quantification is shown on histogram. **p 0.01 (one-way ANOVAwith significance
 0.05). ***p 0.001 (one-way ANOVAwith significance 0.05). n 2 independent experiments.B, Representative photomicrographs from isolectin B4-stained retinal flatmounts from
P12mice pups exposed to hyperoxia fromP7 to P12. Originalmagnification 100. Pups injected intravitreally at P7with THX-Bhad significantly less VOat P12 comparedwith vehicle-injectedmice.
**p0.01 (two-tailedStudent’s t test).n6–9 retinas.C, The levels of Sema3AmRNAexpressionwerequantified fromreal-timePCRofP9whole retinaofmiceexposedornot toOIR, and injected
at P7with vehicle or THX-B.Mice injectedwith THX-B suppressedOIR-induced Sema3AmRNAexpression. **p0.01.n4.D, The levels of TNFmRNAexpressionwere quantified from real-time
PCR of P9 whole retina of mice exposed or not to OIR, and injected at P7 with vehicle or THX-B. Mice injected with THX-B suppressed OIR-induced TNFmRNA expression. ***p 0.001 (two-way
ANOVA with significance 0.05). n 4. E, RBMVEC metabolic/survival assay by MTT. Cultures exposed to CM from proNGF-stimulated rMC-1 cells had increased endothelial cell (EC) death.
Addition of anti-proNGF mAb or p75 NTR inhibitor THX-B reduced proNGF-induced EC death. Controls using rMC-1 CM treated with inhibitors alone or ECs stimulated directly with proNGF had no
effect. ***p 0.001 (two-way ANOVA with significance 0.05). n 6.
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al., 2013), p75 inhibitors lead to normalized angiogenesis and
reduce destructive preretinal angiogenesis. Together, these re-
sults demonstrate that upregulation of proNGF and p75NTR in
Mu¨ller cells during the VO phase of OIR, and upregulation of
p75NTR inMu¨ller cells and astrocytes in theNVphase ofOIR can,
respectively, promote vascular decay and pathological angiogen-
esis in part through TNF and Sema3A.
Discussion
In humans, the pathophysiology of DR is characterized by a cas-
cade of events, such as glial activation, inflammation, RGCdeath,
capillary dropout, and loss of the BRB function causing retinal
edema and ischemia. This ischemia leads to hypoxia and triggers
a subsequent phase of neovascular DR (PDR). However, it is
unknown whether these multiple pathophysiological events are
sequential during disease progression and whether they are re-
lated mechanistically. While literature demonstrated the impact
of glial activation and neuronal dysfunction in the pathogenesis
of DR, and these often occur before measurable vascular abnor-
malities, the sequence of pathological events during disease pro-
gression remains unclear. Here, we demonstrate that prototypic
Mu¨ller cell activation is propagated by p75NTR in a proNGF-
dependentmanner early on at the onset of diabetes (week 1 and 2
following STZ). Moreover, we demonstrate that Mu¨ller cell acti-
vation increases local expression of TNF and 2M, which in-
duce Sema3A in RGCs leading to BRB breakdown, heightened
inflammation, and fluid extravasation into the retina. Fluid ex-
Figure 7. Inhibition of p75 NTR or proNGF reduces the NV area in OIR. A, p75 NTR expression in whole retina analyzed byWestern blot at three time points after OIR (P7-P12 at 75% O2). Levels of
p75 NTR increased significantly during this neovascular phase, relative to control normoxia retinas. Histogram represents quantification. One-way ANOVA with significance 0.05: **p 0.01;
***p 0.001. n 2 independent experiments. B, Distribution of p75 NTR in P17 retina exposed to OIR. p75 NTR (green) was found preferentially in glutamine synthetase (GS)-positive Mu¨ller cells
(red), around the vessels labeled with Lectin (red) and GFAP-positive astrocytes (red). Nuclei are counterstained with DAPI. Top, Original magnification 300. Scale bar, 50m. Bottom, Original
magnification 600. Scale bar, 30m. NFL, Nerve fiber layer. C, Photomicrographs from isolectin B4-stained retinal flat mounts from P17 retinas from OIRmice injected intravitreally at P12 with
THX-Bdemonstrated significantly less avascular areaand less pathologicalNV comparedwith vehicle-treatedmice. Late treatmentusingTHX-BatP14didnot ameliorate revascularization. Scalebar,
100m. *p 0.05 (two-tailed Student’s t test). n 4–6 retinas.
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travasation brings in the retina additional toxic factors, such as
2M, which exacerbate local inflammation.
The combination of all these events results in loss of retinal
structure and irreversible RGC death leading to decreased visual
acuity similar to that in patients with DR (Binet et al., 2013). This
is in agreement with previous studies demonstrating that
Sema3A is secreted by RGCs in response to the proinflammatory
cytokine IL-1, leading to the disruption of the vascular integrity
in a model of proliferative retinopathy (Sitaras et al., 2015). An-
tagonizing p75NTR with THX-B or administration of an inhibi-
tory antibody to proNGF in mice with Type 1 DM, resulted in
diminished Mu¨ller glia activation, curbed TNF, 2M and
Sema3A expression, maintained BRB integrity, and prevented
diabetes-induced neuronal cell and fiber loss.
With respect toNV,whichoccurs at a later stageof thedisease,we
describe important contributions of the p75NTR/proNGF signaling
axis. We describe, using a mouse model of OIR, ligand-dependent
actions of p75NTR on pathological preretinal neovessel formation,
anddemonstrate thatproNGFandp75NTR increase inmice exposed
toOIRand stimulate productionofTNF inMu¨ller cells. This para-
crinemechanismcanaugmentvasculardecayandmaycontribute to
pathological NV as previously reported (Gardiner et al., 2005; Stahl
et al., 2010), events that are reminiscent of DR.
Our data not only corroborate previous studies demonstrat-
ing the pathogenic effects of increased TNF (Gardiner et al.,
2005; Le Moan et al., 2011) and Sema3A (Gardiner et al., 2005)
during the phase of NV but demonstrates a potential regulation
by p75NTR signaling. Both the VO as well as the resulting NV can
be ameliorated by antagonizing p75NTR or proNGF. Together,
these studies validate a novel mechanism of action and provide
evidence of a novel druggable therapeutic target that can amelio-
rate several of the pathological components of DR.
In theDRmodel, the p75/proNGFaxis is upregulated before any
measurable retinaldamage, andbeforeupregulationof retinalTNF
and2MmRNAandprotein, cytokines that are thought to contrib-
ute to the DR pathology. In that sense, p75/proNGF appears to be
upstream of these inflammatory mediators. Inhibition of p75/
proNGF reduces the inflammatory mediators and improves retinal
health. Improved retinal health may then contribute to the long-
term reduction in inflammatorymediators inDR. A similar conclu-
sion would be germane in the OIR model, where the p75/proNGF
axis is upregulated before TNF and Sema3A, and inhibition of
p75/proNGF reduces the mediators and improves retinal health.
Although the therapeutic effect of either p75NTR or proNGF an-
tagonists was generally comparable, discrepancies were observed
likely due to ligand-independent actions of p75NTR. For instance,
although expression of proNGF did not seem to increase during the
second phase of OIR (compared with control room-air raised ani-
mals), inhibition of p75NTR activity via THX-B antagonism success-
fully curbed pathological angiogenesis and promoted normal
revascularization. Of note, there is evidence for ligand-independent
actions of p75NTR in pathological NV in the mouse model of OIR
whereby the -secretase-mediated cleavage of the intracellular do-
main of p75NTR enhances interaction with Siah2 (which prevents
HIF-1degradation) inMu¨ller cells, and increasesVEGFexpression
in the retina. (LeMoanet al., 2011).Thus, antagonizingp75NTRwith
THX-B may prevent cleavage of the p75NTR intracellular domain
permitting Siah2-mediated degradation of HIF-1, which dimin-
ishes VEGF expression and pathological neovessel formation.
The important role of retinal microglia as responder to retinal
injuries has been described previously (Cuenca et al., 2014; Karl-
stetter et al., 2015). In the STZmodel in rats, microglia are found
in retina after 4 weeks of diabetes, and microglia activation leads
to the release of TNF and IL-1, which contributes to vascular
and neuronal cell death (Krady et al., 2005). However, these mi-
croglia events take place after the p75/proNGF axis reported
herein, which largely involve Mu¨ller cells as a first step. We spec-
ulate that it is possible that, by inhibiting the p75/proNGF axis,
microglia activationmay thus also be prevented, due to an overall
improved retinal health.
Figure 8. Model summarizing the etiology of p75 NTR in DR. In a healthy mature retina, the levels of p75 NTR are low. In diabetes, proNGF is significantly increased and activates p75 NTR, which is
upregulated inMu¨ller glial cells andpericytes. InMu¨ller cells, p75 NTR activity triggers the expression/secretion of2Mand TNF.2Mpotentiates proNGF, thus creating a vicious cycle. Upregulated
TNF binds to receptors in RGCs inducing the release of Sema3A and eventual RGC death. Sema3Abinds to its receptor Nrp1 and provokes loosening of endothelial cell junctions in the BRB and leads
to plasma extravasation. In pericytes, p75 NTR activity could presumably trigger dysfunction and loss of vascular integrity, but this was not evaluated in this study. Intravitreal injections of THX-B or
the anti-proNGF mAb in diabetic mice significantly diminished Mu¨ller glia activation, decreased TNF and2M expression, limited Sema3A production, maintained BRB integrity, and prevented
RGC neuronal cell death.
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The data support a model (Fig. 8) explaining the mechanisms
by which p75NTR mediates different phases of the DR. The early
and persistent upregulation of p75NTR, mainly in Mu¨ller glial
cells, plays a pivotal role in disrupting neuro-glia-vascular unit in
the DR. More specifically, p75NTR signaling promotes, in a
ligand-dependent manner, production of the inflammatory cy-
tokines TNF and 2M and Sema3A, leading to RGC death, BRB
breakdown, and edema. Similarly, p75NTR activity contributes to
retinal VO andNV via increased TNF and Sema3A production.
To illustrate this phenomenon, we propose a hypothetical model
to integrate these observations (Fig. 8). In DR, resident Mu¨ller
glia undergo activation and gliosis augmenting the production of
p75NTR. Activated Mu¨ller cells rapidly increase the levels of
proNGF, and autocrine binding of proNGF to p75NTR promotes
the production and release of proinflammatory cytokines, such as
TNF and 2M. TNF and 2M act via two different paracrine
mechanisms. First, TNF binds to its receptor on RGCs and
prompts the secretion of the vascular cue Sema3A. Excessive ac-
cumulation of TNF and 2M ultimately causes RGC death and
the secretion of Sema3A fromRGCs, which influence endothelial
cells by binding, most likely, to its receptor Neuropilin-1 (Cerani
et al., 2013). Sema3A causes early BRB breakdown and plasma
extravasation. Ligand-dependent production of inflammatory
cytokines, RGC death, BRB breakdown, and edema were signifi-
cantly decreased by treatment with anti-proNGF mAb or the
p75NTR antagonist THX-B. Second, TNF acts directly on endo-
thelial cells inducing cell death, which contribute to vessel loss
during the first phase of the vascular component of the disease.
Both anti-proNGF mAb and THX-B treatments also reduced
pathological NV. In conclusion, p75NTR and proNGF are key
mediators at different stages of the DR. These antagonists may be
novel therapeutic targets that offer a wide range spectrum of
action and an alternative approach to the VEGF-based strategy.
In conclusion, our data identify a novel mechanism implicat-
ing neuronal, glial, and vascular interplay in the pathogenesis of
DR. In doing so, we provide evidence for p75 as a promising
therapeutic target to counter several stages of DR.
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